• 1
    Liesegang TJ. Herpes simplex virus epidemiology and ocular importance. Cornea 2001; 20: 113.
  • 2
    Barron BA, Gee L, Hauck WW et al. Herpetic Eye Disease Study. A controlled trial of oral acyclovir for herpes simplex stromal keratitis. Ophthalmology 1994; 101: 187182.
  • 3
    Wilhelmus KR, Gee L, Hauck WW et al., Herpetic Eye Disease Study. A controlled trial of topical corticosteroids for herpes simplex stromal keratitis. Ophthalmology 1994; 101: 188395, discussion 1895-6.
  • 4
    Sozen E, Avunduk AM, Akyol N. Comparison of efficacy of oral valacyclovir and topical acyclovir in the treatment of herpes simplex keratitis: a randomized clinical trial. Chemotherapy 2006; 52: 2931.
  • 5
    Herpetic Eye Disease Study Group. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. N Engl J Med 1998; 339: 3006.
  • 6
    Miserocchi E, Modorati G, Galli L, Rama P. Efficacy of valacyclovir vs acyclovir for the prevention of recurrent herpes simplex virus eye disease: a pilot study. Am J Ophthalmol 2007; 144: 54751.
  • 7
    Itahashi M, Higaki S, Shimomura Y. Effects of anti herpetic drugs on mice with herpetic epithelial keratitis after reactivation of herpes simplex virus type 1. Semin Ophthalmol 2008; 23: 2417.
  • 8
    Liesegang TJ, Melton LJ, Daly PJ, Ilstrup DM. Epidemiology of ocular herpes simplex. Incidence in Rochester, Minn, 1950 through 1982. Arch Ophthalmol 1989; 107: 11559.
  • 9
    Herpetic Eye Disease Study Group. Predictors of recurrent herpes simplex virus keratitis. Cornea 2001; 20: 1238.
  • 10
    Gilbert C, Bestman-Smith J, Boivin G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Updat 2002; 5: 88114.
  • 11
    Fife KH, Crumpacker CS, Mertz GJ, Hill EL, Boone GS. Recurrence and resistance patterns of herpes simplex virus following cessation of > or =6 years of chronic suppression with acyclovir. Acyclovir Study Group. J Infect Dis 1994; 169: 133841.
  • 12
    Christophers J, Clayton J, Craske J et al. Survey of resistance of herpes simplex virus to acyclovir in northwest England. Antimicrob Agents Chemother 1998; 42: 86872.
  • 13
    Bacon TH, Levin MJ, Leary JJ, Sarisky RT, Sutton D. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev 2003; 16: 11428.
  • 14
    Stránská R, Schuurman R, Nienhuis E et al. Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization. J Clin Virol 2005; 32: 718.
  • 15
    Ziyaeyan M, Alborzi A, Japoni A et al. Frequency of acyclovir-resistant herpes simplex viruses isolated from the general immunocompetent population and patients with acquired immunodeficiency syndrome. Int J Dermatol 2007; 46: 12636.
  • 16
    Reyes M, Shaik NS, Graber JM et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med 2003; 163: 7680.
  • 17
    Charles SJ, Gray JJ. Ocular herpes simplex virus infections: reduced sensitivity to acyclovir in primary disease. Br J Ophthalmol 1990; 74: 2868.
  • 18
    Duan R, De Vries RD, Osterhaus AD, Remeijer L, Verjans GM. Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis. J Infect Dis 2008; 198: 65963.
  • 19
    Balfour HH, Benson C, Braun J et al. Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. J Acquir Immune Defic Syndr 1994; 7: 25460.
  • 20
    Pratuangtham S, Bornstein SM, Boyer KM, McAuley JB, Deutsch TA, Gotoff SP. Treatment of acyclovir-resistant herpes simplex virus keratitis in a patient with Wiskott-Aldrich syndrome. Clin Infect Dis 1997; 25: 12578.
  • 21
    Alvarez-McLeod A, Havlik J, Drew KE. Foscarnet treatment of genital infection due to acyclovir-resistant herpes simplex virus type 2 in a pregnant patient with AIDS: case report. Clin Infect Dis 1999; 29: 9378.
  • 22
    Arevalo JF, Gonzalez C, Capparelli EV et al. Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. J Infect Dis 1995; 172: 9516.
  • 23
    Levin MJ, Bacon TH, Leary JJ. Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients. Clin Infect Dis 2004; 39 (Suppl. 5): S24857.
  • 24
    Sarisky RT, Cano R, Nguyen TT et al. Biochemical characterization of a virus isolate, recovered from a patient with herpes keratitis, that was clinically resistant to acyclovir. Clin Infect Dis 2001; 33: 20349.
  • 25
    Fabricius EM. Foscarnet eyedrops in recurrence prophylaxis of herpes simplex virus keratitis. Acta Ophthalmol Scand 1998; 76: 7557.
  • 26
    Behrens-Baumann W. Phosphonoformate (foscarnet, PFA) versus trifluorthymidine in the treatment of keratitis dendritica in the human. A double-blind, randomized, preliminary trial. Acta Ophthalmol 1992; 70: 6902.
  • 27
    Wilhelmus KR. Therapeutic interventions for herpes simplex virus epithelial keratitis. Cochrane Database Syst Rev 2008; Issue 1: CD002898.
  • 28
    Kaufman HE, Varnell ED, Thompson HW. Trifluridine, cidofovir, and penciclovir in the treatment of experimental herpetic keratitis. Arch Ophthalmol 1998; 116: 77780.
  • 29
    Boisjoly HM, Park NH, Pavan-Langston D, De Clercq E. Herpes simplex acyclovir-resistant mutant in experimental keratouveitis. Arch Ophthalmol 1983; 101: 17826.
  • 30
    Meerbach A, Wutzler P, Gruhn B. Brivudin (ZostexR) in the treatment of herpes zoster in immunosuppressed patients. Antiviral Res 2007; 74: A75A75.